Anthony Magliulo, MD
Internal Medicine · Kailua, HINPI 1558471342
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 656 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 17.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $2,258 and has fallen 92.2% since, to $177 in 2025. Among internal medicine clinicians in HI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 656 payments — averaging $16.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Kowa Pharmaceuticals America, Inc.$2K
- Lilly USA, LLC$2K
- Novo Nordisk$1K
- Amgen$1K
- AstraZeneca$884
- GSK$664
- plus $3K from 25 others
What the payments were for
- Food & beverage$10,619100%
- Education$110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Kowa Pharmaceuticals America, Inc. | 145 | $1,888 |
| Lilly USA, LLC | 77 | $1,503 |
| Novo Nordisk | 85 | $1,378 |
| Amgen(2 entities) | 54 | $1,056 |
| AstraZeneca | 48 | $884 |
| GSK | 54 | $664 |
| Johnson & Johnson | 39 | $498 |
| Amarin Pharma, Inc. | 29 | $485 |
| Pfizer | 20 | $381 |
| Bayer | 19 | $372 |
| Boehringer Ingelheim | 12 | $233 |
| Novartis | 11 | $228 |
| Esperion Therapeutics, Inc. | 13 | $206 |
| Sanofi-aventis U.S. LLC | 10 | $166 |
| Astellas Pharma US Inc | 5 | $92 |
| Merck | 5 | $87 |
| E.r. Squibb & Sons, L.L.C. | 4 | $68 |
| Teva Pharmaceuticals USA, Inc. | 4 | $67 |
| Radius Health, Inc. | 4 | $66 |
| Abbott | 3 | $54 |
| AbbVie(2 entities) | 3 | $48 |
| Ironwood Pharmaceuticals, Inc | 2 | $39 |
| Eisai Inc. | 2 | $28 |
| Idorsia Pharmaceuticals US Inc | 1 | $25 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Smith+Nephew | 1 | $20 |
| Dexcom, Inc. | 1 | $19 |
| Exact Sciences | 1 | $18 |
| Mylan Specialty L.p. | 1 | $16 |
| Genentech USA, Inc. | 1 | $15 |
| Travere Therapeutics, Inc. | 1 | $6 |
How this compares
$10,631 in reported general payments places this provider in the 90th percentile of 655 internal medicine providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 96 | $152,662 |
| TrulicityDulaglutide | 52 | $109,054 |
| JardianceEmpagliflozin | 50 | $81,667 |
| OtezlaApremilast | 13 | $65,113 |
| MounjaroTirzepatide | 34 | $62,123 |
| EliquisApixaban | 47 | $52,701 |
| XareltoRivaroxaban | 37 | $50,061 |
| Evenity (2 Syringes)Romosozumab-Aqqg | 12 | $30,398 |
| ProliaDenosumab | 16 | $27,682 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 36 | $26,625 |
| KerendiaFinerenone | 14 | $22,695 |
| FarxigaDapagliflozin Propanediol | 14 | $20,837 |
| RybelsusSemaglutide | 13 | $20,652 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $19,237 |
| Atorvastatin Calcium | 621 | $14,020 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,378 | $173,314109 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $1,503 | $171,17786 claims |
| AmgenOtezla, Evenity (2 Syringes), Prolia | $1,056 | $123,19341 claims |
| Boehringer IngelheimJardiance | $233 | $81,66750 claims |
| PfizerEliquis | $381 | $52,70147 claims |
| Johnson & JohnsonXarelto | $498 | $50,06137 claims |
| GSKTrelegy Ellipta, Arexvy, Incruse Ellipta | $664 | $37,71989 claims |
| BayerKerendia | $372 | $22,69514 claims |
| AstraZenecaFarxiga | $884 | $20,83714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 655 internal medicine providers in Hawaii.
Other internal medicine in Kailua
- Scott StromattKamuela$385K
- Keith WooHonolulu$106K
- Ronald PerryHonolulu$102K
- Laurie TomHonolulu$95K
- Yusuke MiyataniHonolulu$80K
- Joshua TanHonolulu$76K
- Jose de LeonHonolulu$52K
- Peter DeeHonolulu$49K
- James LumengHonolulu$45K
- Charles ZerezHonolulu$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.